Vitamin K antagonists in children with heart disease: height and VKORC1 genotype are the main determinants of the warfarin dose requirement.

Managing vitamin K antagonist (VKA) therapy is challenging in children because of a narrow therapeutic range and wide inter- and intra-individual variability in dose response. Only a few small studies have investigated the effect of nongenetic and genetic factors on the dose response to VKAs in children. In a cohort study including 118 children (median age 9 years; range, 3 months-18 years) mostly with cardiac disease, we evaluated by multivariate analysis the relative contribution of nongenetic factors and VKORC1/CYP2C9/CYP4F2 genotypes on warfarin (n = 83) or fluindione (n = 35) maintenance dose and the influence of these factors on the time spent within/above/below the range. The results showed that height, target international normalized ratio and VKORC1 and CYP2C9 genotypes were the main determinants of warfarin dose requirement, accounting for 48.1%, 4.4%, 18.2%, and 2.0% of variability, respectively, and explaining 69.7% of the variability. Our model predicted the warfarin dose within 7 mg/wk in 86.7% of patients. None of the covariates was associated with the time spent above or below the international normalized ratio range. Whether this model predicts accurately the effective maintenance dose is currently being investigated.

[1]  F. Kirkham,et al.  Antithrombotic therapy in neonates and children: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). , 2008, Chest.

[2]  D. Tregouet,et al.  Cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity. , 2005, Blood.

[3]  M. Loriot,et al.  Genetic Factors (VKORC1, CYP2C9, EPHX1, and CYP4F2) Are Predictor Variables for Warfarin Response in Very Elderly, Frail Inpatients , 2010, Clinical pharmacology and therapeutics.

[4]  D. Stafford.  The vitamin K cycle , 2005, Journal of thrombosis and haemostasis : JTH.

[5]  M. Rieder,et al.  Use of Pharmacogenetic and Clinical Factors to Predict the Therapeutic Dose of Warfarin , 2008, Clinical pharmacology and therapeutics.

[6]  S. Bergan,et al.  Oral anticoagulation with warfarin is significantly influenced by steroids and CYP2C9 polymorphisms in children with cancer , 2008, Pediatric blood & cancer.

[7]  Mario Plebani,et al.  VKORC1, CYP2C9 and CYP4F2 genetic-based algorithm for warfarin dosing: an Italian retrospective study. , 2011, Pharmacogenomics.

[8]  M. Rieder,et al.  A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose. , 2008, Blood.

[9]  Deborah A Nickerson,et al.  Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. , 2005, The New England journal of medicine.

[10]  Masato Taguchi,et al.  Effect of the VKORC1 genotype on warfarin dose requirements in Japanese pediatric patients. , 2011, Drug metabolism and pharmacokinetics.

[11]  G. Kearns,et al.  Developmental pharmacokinetics. , 2011, Handbook of experimental pharmacology.

[12]  M. Crowther,et al.  The "age" of understanding VKA dose. , 2010, Blood.

[13]  K. Kosaki,et al.  1173C>T Polymorphism in VKORC1 Modulates the Required Warfarin Dose , 2006, Pediatric Cardiology.

[14]  Y. Turpaz,et al.  CYP4F2 genetic variant alters required warfarin dose. , 2008, Blood.

[15]  J. Corral,et al.  Pharmacogenetic relevance of CYP4F2 V433M polymorphism on acenocoumarol therapy. , 2009, Blood.

[16]  C. Thorn,et al.  Dosing Algorithms to Predict Warfarin Maintenance Dose in Caucasians and African Americans , 2008, Clinical pharmacology and therapeutics.

[17]  S. Higuchi,et al.  Genetic polymorphism of cytochrome P450s, CYP2C19, and CYP2C9 in a Japanese population. , 1998, Therapeutic drug monitoring.

[18]  Nicole Soranzo,et al.  A Genome-Wide Association Study Confirms VKORC1, CYP2C9, and CYP4F2 as Principal Genetic Determinants of Warfarin Dose , 2009, PLoS genetics.

[19]  Peter Wood,et al.  The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. , 2005, Blood.

[20]  L. Becquemont.  Evidence for a pharmacogenetic adapted dose of oral anticoagulant in routine medical practice , 2008, European Journal of Clinical Pharmacology.

[21]  Julie A. Johnson,et al.  Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements , 2006, Clinical pharmacology and therapeutics.

[22]  R. Altman,et al.  Estimation of the warfarin dose with clinical and pharmacogenetic data. , 2009, The New England journal of medicine.

[23]  J. Losay,et al.  Acénocoumarol (Sintrom®) et fluindione (Previscan®) en pédiatrie après intervention de chirurgie cardiaque , 2002 .

[24]  V. Marzinotto,et al.  Analysis of warfarin therapy in pediatric patients: A prospective cohort study of 319 patients. , 1999, Blood.

[25]  Panos Deloukas,et al.  The largest prospective warfarin-treated cohort supports genetic forecasting. , 2009, Blood.

[26]  B. Horne,et al.  An evaluation of nine genetic variants related to metabolism and mechanism of action of warfarin as applied to stable dose prediction , 2010, Journal of Thrombosis and Thrombolysis.

[27]  F R Rosendaal,et al.  A Method to Determine the Optimal Intensity of Oral Anticoagulant Therapy , 1993, Thrombosis and Haemostasis.

[28]  Dan M Roden,et al.  Genetic determinants of response to warfarin during initial anticoagulation. , 2008, The New England journal of medicine.

[29]  J. Lindh,et al.  Influence of CYP2C9 genotype on warfarin dose requirements—a systematic review and meta-analysis , 2009, European Journal of Clinical Pharmacology.

[30]  S. Ishikawa,et al.  Developmental changes in pharmacokinetics and pharmacodynamics of warfarin enantiomers in Japanese children , 2000, Clinical pharmacology and therapeutics.

[31]  Lesley G Mitchell,et al.  In pediatric patients, age has more impact on dosing of vitamin K antagonists than VKORC1 or CYP2C9 genotypes. , 2010, Blood.

[32]  P. Monagle,et al.  Anticoagulation in neonates and children: Pitfalls and dilemmas. , 2010, Blood reviews.

[33]  D. Roden,et al.  Relative contribution of CYP2C9 and VKORC1 genotypes and early INR response to the prediction of warfarin sensitivity during initiation of therapy. , 2009, Blood.

[34]  M. Margaglione,et al.  A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin. , 2005, Blood.

[35]  M. Taljaard,et al.  A regression model to predict warfarin dose from clinical variables and polymorphisms in CYP2C9, CYP4F2, and VKORC1: Derivation in a sample with predominantly a history of venous thromboembolism. , 2010, Thrombosis research.

[36]  M. Loriot,et al.  No clear link between VKORC1 genetic polymorphism and the risk of venous thrombosis or peripheral arterial disease , 2008, Thrombosis and Haemostasis.